Sophie Stocker

Dr. Sophie Stocker

School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2013 in Annual Review of Pharmacology and Toxicology
Verified
Journal Article
Closed access
KMKari M. Morrissey
Kari M. Morrissey
Sophie StockerSophie Stocker
Sophie Stocker
MWMatthias B. Wittwer
Matthias B. Wittwer
LXLu Xu
Lu Xu
KGKathleen M. Giacomini
Kathleen M. Giacomini
The kidney plays a vital role in the body's defense against potentially toxic xenobiotics and metabolic waste products through elimination pathways. In particular, secretory transporters in the proximal tubule are major determinants of the disposition of xenobiotics, including many prescription drugs. In the past decade, considerable progress has been made in understanding the impact of renal transporters on the disposition of many clinically used drugs. In addition, renal transporters have been implicated as sites for numerous clinically important drug-drug interactions. This review begins with a description of renal drug handling and presents relevant equations for the calculation of renal clearance, including filtration and secretory clearance. In addition, data on the localization, expression, substrates, and inhibitors of renal drug transporters are tabulated. The recent US Food and Drug Administration drug-drug interaction draft guidance as it pertains to the study of renal drug transporters is presented. Renal drug elimination in special populations and transporter splicing variants are also described.

22 June 2018 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
TLTom N. Lea-Henry
Tom N. Lea-Henry
JCJane E. Carland
Jane E. Carland
Sophie StockerSophie Stocker
Sophie Stocker
JSJacob Sevastos
Jacob Sevastos
DRDarren M. Roberts
Darren M. Roberts
Kidney disease is an increasingly common comorbidity that alters the pharmacokinetics of many drugs. Prescribing to patients with kidney disease requires knowledge about the drug, the extent of the patient’s altered physiology, and pharmacokinetic principles that influence the design of dosing regimens. There are multiple physiologic effects of impaired kidney function, and the extent to which they occur in an individual at any given time can be difficult to define. Although some guidelines are available for dosing in kidney disease, they may be on the basis of limited data or not widely applicable, and therefore, an understanding of pharmacokinetic principles and how to apply them is important to the practicing clinician. Whether kidney disease is acute or chronic, drug clearance decreases, and the volume of distribution may remain the same or increase. Although in CKD, these changes progress relatively slowly, they are dynamic in AKI, and recovery is possible depending on the etiology and treatments. This, and the use of kidney replacement therapies further complicate attempts to quantify drug clearance at the time of prescribing and dosing in AKI. The required change in the dosing regimen can be estimated or even quantitated in certain instances through the application of pharmacokinetic principles to guide rational drug dosing. This offers an opportunity to provide personalized medical care and minimizes adverse drug events from either under- or overdosing. We discuss the principles of pharmacokinetics that are fundamental for the design of an appropriate dosing regimen in this review.

8 August 2018 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
MZMaciej J. Zamek‐Gliszczynski
Maciej J. Zamek‐Gliszczynski
MTMitchell E. Taub
Mitchell E. Taub
PCParesh P. Chothe
Paresh P. Chothe
XCXiaoyan Chu
Xiaoyan Chu
KGKathleen M. Giacomini
Kathleen M. Giacomini
ICInternational Transporter Consortium
International Transporter Consortium

1 January 2007 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
RDRichard Day
Richard Day
GGGarry G. Graham
Garry G. Graham
MHMark Hicks
Mark Hicks
AMAndrew J. McLachlan
Andrew J. McLachlan
Sophie StockerSophie Stocker
Sophie Stocker
KWKenneth M. Williams
Kenneth M. Williams

17 October 2012 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
Sophie StockerSophie Stocker
Sophie Stocker
KMK M Morrissey
K M Morrissey
SYSook Wah Yee
Sook Wah Yee
RCR A Castro
R A Castro
LXL Xu
L Xu
KGK M Giacomini
K M Giacomini

1 December 2015 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
WCWen-Hung Chung
Wen-Hung Chung
WCWan-Chun Chang
Wan-Chun Chang
Sophie StockerSophie Stocker
Sophie Stocker
CJChiun-Gung Juo
Chiun-Gung Juo
GGGarry G Graham
Garry G Graham
Shuen-Iu HungShuen-Iu Hung
Shuen-Iu Hung
Objective Allopurinol, an antihyperuricaemic agent, is one of the common causes of life-threatening severe cutaneous adverse reactions (SCAR), including drug rash with eosinophilia and systemic symptoms (DRESS), Stevens–Johnson syndrome (SJS) and toxic epidermal necrosis (TEN). The prognostic factors for allopurinol-related SCAR remain unclear. This study aimed to investigate the relationship of dosing, renal function, plasma levels of oxypurinol and granulysin (a cytotoxic protein of SJS/TEN), the disease severity and mortality in allopurinol-SCAR. Methods We prospectively enrolled 48 patients with allopurinol-SCAR (26 SJS/TEN and 22 DRESS) and 138 allopurinol-tolerant controls from 2007 to 2012. The human leucocyte antigen (HLA)-B*58:01 status, plasma concentrations of oxypurinol and granulysin were determined. Results In this cohort, HLA-B*58:01 was strongly associated with allopurinol-SCAR (p<0.001, OR (95% CI) 109 (25 to 481)); however, the initial/maintenance dosages showed no relationship with the disease. Poor renal function was significantly associated with the delayed clearance of plasma oxypurinol, and increased the risk of allopurinol-SCAR (p<0.001, OR (95% CI) 8.0 (3.9 to 17)). Sustained high levels of oxypurinol after allopurinol withdrawal correlated with the poor prognosis of allopurinol-SCAR. In particular, the increased plasma levels of oxypurinol and granulysin linked to the high mortality of allopurinol-SJS/TEN (p<0.01), and strongly associated with prolonged cutaneous reactions in allopurinol-DRESS (p<0.05). Conclusions Impaired renal function and increased plasma levels of oxypurinol and granulysin correlated with the poor prognosis of allopurinol-SCAR. Allopurinol prescription is suggested to be avoided in subjects with renal insufficiency and HLA-B*58:01 carriers. An early intervention to increase the clearance of plasma oxypurinol may improve the prognosis of allopurinol-SCAR.